Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Autoimmune Disorders01:29

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Disorders of the Nervous Tissue01:28

Disorders of the Nervous Tissue

Nervous tissue is a vital component of the human body's communication system, enabling us to perceive and respond to stimuli. However, like all other tissues, it is vulnerable to disorders and diseases that can significantly impact our neurological functioning.
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Outcome of treatment with trametinib in adults with histiocytic neoplasms in the United Kingdom.

British journal of haematology·2026
Same author

Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Cambridge neuroscience symposium: Interventions and recovery.

Brain and neuroscience advances·2025
Same author

Ageing and remyelination failure in people with multiple sclerosis.

Brain : a journal of neurology·2025
Same author

Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis.

Brain : a journal of neurology·2025
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Same journal

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Lancet (London, England)·2026
Same journal

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

Lancet (London, England)·2026
Ver todos los artículos relacionados

Video Experimental Relacionado

Updated: Jun 28, 2026

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

La esclerosis múltiple es la esclerosis múltiple.

Alastair Compston1, Alasdair Coles

  • 1Department of Clinical Neurosciences, University of Cambridge Clinical School, Addenbrooke's Hospital, Cambridge, UK.

Lancet (London, England)
|October 31, 2008
PubMed
Resumen
Este resumen es generado por máquina.

La esclerosis múltiple implica inflamación y neurodegeneración en el sistema nervioso central. Los tratamientos actuales manejan las recaídas pero no la progresión de la discapacidad a largo plazo, lo que requiere nuevas estrategias terapéuticas.

Más Videos Relacionados

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

Videos de Experimentos Relacionados

Last Updated: Jun 28, 2026

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

Área de la Ciencia:

  • La neurociencia es la neurociencia.
  • Inmunología Inmunología.
  • Neurología Neurología.

Sus antecedentes:

  • La esclerosis múltiple (EM) es un trastorno inflamatorio del sistema nervioso central caracterizado por desmielinización y daño axonal.
  • La esclerosis múltiple temprana implica inflamación transitoria y remielinización incompleta, lo que lleva a una disfunción neurológica recidivante-remitente.
  • La esclerosis múltiple crónica progresa debido a la activación microglial y la neurodegeneración, causando una acumulación de discapacidad irreversible.

Objetivo del estudio:

  • Revisar los mecanismos patológicos y la progresión clínica de la esclerosis múltiple.
  • Para evaluar la eficacia de los agentes modificadores de enfermedades actuales.
  • Para resaltar la necesidad de estrategias terapéuticas basadas en el mecanismo en la EM.

Principales métodos:

  • Revisión de la literatura existente sobre la fisiopatología y el tratamiento de la esclerosis múltiple.
  • Análisis de hallazgos paraclínicos que incluyen resonancia magnética, potenciales evocados y análisis de líquido cefalorraquídeo.
  • Discusión de los factores genéticos y ambientales que contribuyen a la EM.

Principales resultados:

  • La patología de la EM pasa de la inflamación transitoria a la neurodegeneración crónica.
  • Las investigaciones paraclínicas revelan lesiones inflamatorias, pérdida axonal y síntesis de anticuerpos intratecales.
  • Los agentes modificadores de la enfermedad actuales reducen principalmente la frecuencia de recaída, con un impacto limitado en los déficits fijos o la progresión a largo plazo.

Conclusiones:

  • La investigación futura de la esclerosis múltiple debe centrarse en una taxonomía basada en el mecanismo para mejorar el tratamiento.
  • Se necesitan nuevas terapias para abordar la neurodegeneración y la acumulación de discapacidad en todas las etapas de la EM.
  • Comprender la compleja interacción de factores genéticos y ambientales es crucial para desarrollar intervenciones efectivas para la EM.